References in periodicals archive ?
Their investigational new drug is the first GSNOR inhibitor to enter human clinical development.
It is the first company to discover and develop small molecules targeting GSNOR.
N91115 is the first oral GSNOR inhibitor to enter clinical development, representing an important step towards identifying treatments to address a disease with significant unmet need.
A Novel GSNOR Inhibitor with Potent Bronchodilatory Effects and CFTR Potentiation Activity
Intestinal Current Measurement to Assess Modulation of F508del CFTR Function by GSNOR Inhibitor Treatment (In Vivo)
N30 Pharma has developed a novel portfolio of GSNOR inhibitor drugs that conserve S-nitrosoglutathione (GSNO), an endogenous, signaling molecule that has been shown to modulate the function of key proteins involved in the pathophysiology of CF through S-nitrosation.
N30 Pharma's GSNOR inhibitors have a number of potential effects in CF.
N30 Pharma's drugs restore GSNO levels by inhibiting GSNOR, the enzyme in the body that breaks down GSNO.
N30 Pharma's GSNOR inhibitors have dual effects in cystic fibrosis.
GSNOR is a critical enzyme in the endogenous nitric oxide pathway, and its activity is thought to be important in human respiratory, gastrointestinal and cardiovascular disease.
In asthmatics, GSNOR up-regulation and decreased GSNO levels have been shown to contribute to respiratory disease, and genetic variants of GSNOR have been correlated with disease susceptibility and poor response to therapy.
N6022 is a highly potent, selective and reversible inhibitor of GSNOR.
Medical browser ?
- Grutz, Otto
- Grynfeltt triangle
- Grynfeltt, Joseph C.
- Grzybowski, M.
- gs antigen
- G-series nerve agents
- gSowa rigpa
- GTP cyclohydrolase
- GU71u344 virus
- GU71u350 virus
- gua sha
Full browser ?